Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in Gut Retrieve available abstracts of 119 articles: HTML format

Single Articles

May 2026
1. CHEN R, Turpin W, Allez M, Silverberg MS, et al
   From preclinical phase of Crohn's disease to postoperative recurrence: shared mechanisms and potential interventions.
   Gut. 2026 May 28:gutjnl-2025-337981. doi: 10.1136/gutjnl-2025-337981.
   PubMed     Abstract available
   
   
   April 2026
2. ZHANG J, Hu J, Tang X, Ruan Y, et al
   Quantifying artificial sweeteners and emulsifiers in Crohn's disease and its relationship with disease activity: the ENIGMA study - a novel and targeted approach.
   Gut. 2026 Apr 8:gutjnl-2024-333999. doi: 10.1136/gutjnl-2024-333999.
   PubMed     Abstract available
   
   
   
3. BIRDA CL, Jena A, Torres J, Ng SC, et al
   Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases.
   Gut. 2026;75:1055-1066.
   PubMed     Abstract available
   
   
   March 2026
4. HENS B, D'Haens G, Ungaro RC, Colombel JF, et al
   Screening for preclinical Crohn's disease based on capsule endoscopy is not yet ready.
   Gut. 2026 Mar 2:gutjnl-2026-338303. doi: 10.1136/gutjnl-2026-338303.
   PubMed    
   
   
   February 2026
5. 
   Correction: Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
   Gut. 2026 Feb 18:gutjnl-2024-332043corr1. doi: 10.1136/gutjnl-2024-332043.
   PubMed    
   
   
   
6. POWELL N
   Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted?
   Gut. 2026 Feb 13:gutjnl-2025-336049. doi: 10.1136/gutjnl-2025-336049.
   PubMed     Abstract available
   
   
   
7. DAI C, Huang YH, Jiang M
   Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives.
   Gut. 2026 Feb 3:gutjnl-2026-338123. doi: 10.1136/gutjnl-2026-338123.
   PubMed    
   
   
   
8. TURNER D, Kenigsberg S, Focht G, Croitoru K, et al
   Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.
   Gut. 2026 Feb 3:gutjnl-2026-338188. doi: 10.1136/gutjnl-2026-338188.
   PubMed    
   
   
   January 2026
9. IACUCCI M, Zammarchi I, Pugliano CL, Santacroce G, et al
   Shaping the future of postoperative recurrence in Crohn's disease: personalised approaches with AI-enabled imaging and multi-omics.
   Gut. 2026 Jan 27:gutjnl-2025-337171. doi: 10.1136/gutjnl-2025-337171.
   PubMed     Abstract available
   
   
   
10. PARIGI TL, Cominelli F
    Role of TL1A in perianal fistulising Crohn's disease: a new therapeutic target?
    Gut. 2026 Jan 23:gutjnl-2025-337684. doi: 10.1136/gutjnl-2025-337684.
    PubMed    
    
    
    
11. CONSTANTINE-COOKE N, Gros B, Plevris N, Williams LJ, et al
    Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.
    Gut. 2026 Jan 19:gutjnl-2025-337846. doi: 10.1136/gutjnl-2025-337846.
    PubMed     Abstract available
    
    
    
12. ZHANG J, Mak JWY, Ng SC
    Gut microbiome in IBD: past, present and the future.
    Gut. 2026;75:398-410.
    PubMed     Abstract available
    
    
    
13. MAYORGA L, Noguera Segura A, Campderros L, Pons-Tarin M, et al
    Distinct microbial mediators link diet to inflammation in Crohn's disease and ulcerative colitis.
    Gut. 2026 Jan 6:gutjnl-2025-337480. doi: 10.1136/gutjnl-2025-337480.
    PubMed     Abstract available
    
    
    December 2025
14. NOH Y, Choi A, Lee H, Yon DK, et al
    Proton pump inhibitors use and risk of inflammatory bowel disease in children.
    Gut. 2025 Dec 31:gutjnl-2025-337345. doi: 10.1136/gutjnl-2025-337345.
    PubMed    
    
    
    
15. GUDINO V, Cho JW, Caballol B, Sanzo-Machuca A, et al
    TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.
    Gut. 2025 Dec 25:gutjnl-2025-336246. doi: 10.1136/gutjnl-2025-336246.
    PubMed     Abstract available
    
    
    
16. TAN H, Huang L, Wang J, Huang H, et al
    Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation.
    Gut. 2025 Dec 25:gutjnl-2025-335887. doi: 10.1136/gutjnl-2025-335887.
    PubMed     Abstract available
    
    
    
17. ZHOU L, Nie J, Feng Z, Li R, et al
    Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn's disease.
    Gut. 2025 Dec 13:gutjnl-2025-336415. doi: 10.1136/gutjnl-2025-336415.
    PubMed     Abstract available
    
    
    
18. TURNER D, Kenigsberg S, Focht G, Turpin W, et al
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.
    Gut. 2025 Dec 11:gutjnl-2025-336368. doi: 10.1136/gutjnl-2025-336368.
    PubMed     Abstract available
    
    
    
19. SCHREIBER S, Aden K, Tran F, Rosenstiel P, et al
    Rise of precision medicine: can it deliver on its promise in IBD?
    Gut. 2025;75:176-188.
    PubMed     Abstract available
    
    
    
20. MIYAUCHI E, Taida T, Uchiyama K, Nakanishi Y, et al
    Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota.
    Gut. 2025;75:46-56.
    PubMed     Abstract available
    
    
    
21. DE LUCA R, Arre V, Nardone S, Incerpi S, et al
    Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.
    Gut. 2025;75:161-175.
    PubMed     Abstract available
    
    
    October 2025
22. BRAGA-NETO MB, Qazi T, Fulmer C, Holubar SD, et al
    Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.
    Gut. 2025;74:1905-1915.
    PubMed     Abstract available
    
    
    September 2025
23. 
    Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025 Sep 26:gutjnl-2024-334395corr1. doi: 10.1136/gutjnl-2024-334395.
    PubMed    
    
    
    
24. ASHTON JJ, Green Z, Beattie RM
    British Society of Gastroenterology adult guidelines on inflammatory bowel disease: what can we learn for children and young people?
    Gut. 2025 Sep 12:gutjnl-2025-336739. doi: 10.1136/gutjnl-2025-336739.
    PubMed    
    
    
    
25. HAZIME H, Ducasa GM, Santander AM, Brito N, et al
    DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-associated dysbiosis.
    Gut. 2025;74:1589-1601.
    PubMed     Abstract available
    
    
    
26. GONZALEZ-ACERA M, Patankar JV, Erkert L, Cineus R, et al
    Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD.
    Gut. 2025;74:1602-1615.
    PubMed     Abstract available
    
    
    August 2025
27. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global consensus statement on the management of pregnancy in inflammatory bowel disease.
    Gut. 2025 Aug 28:gutjnl-2025-336402. doi: 10.1136/gutjnl-2025-336402.
    PubMed     Abstract available
    
    
    July 2025
28. MO M, Sun J, Mikulic I, Ludvigsson JF, et al
    Inflammatory bowel disease linked to accelerated cognitive decline in individuals with dementia: a nationwide cohort study.
    Gut. 2025 Jul 11:gutjnl-2025-335370. doi: 10.1136/gutjnl-2025-335370.
    PubMed    
    
    
    
29. 
    Correction: Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025;74:e16.
    PubMed    
    
    
    
30. KOU F, Li XY, Feng Z, Hua J, et al
    GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism.
    Gut. 2025;74:1279-1292.
    PubMed     Abstract available
    
    
    
31. BOURGONJE AR, Andreu-Sanchez S, Gacesa R, Innocenti G, et al
    Crohn's disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset.
    Gut. 2025 Jul 2:gutjnl-2024-334362. doi: 10.1136/gutjnl-2024-334362.
    PubMed     Abstract available
    
    
    June 2025
32. PAL P, Mateen MA, Pooja K, Marri UK, et al
    Small intestinal contrast ultrasound versus imaging and enteroscopy in Crohn's disease.
    Gut. 2025 Jun 27:gutjnl-2025-335697. doi: 10.1136/gutjnl-2025-335697.
    PubMed    
    
    
    
33. MORAN GW, Gordon M, Sinopolou V, Radford SJ, et al
    British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025;74.
    PubMed     Abstract available
    
    
    
34. SUN Y, Huang X, Zhang Y, Bao W, et al
    Enterococcus faecalis hijacks FABP2 to activate quorum-sensing signals and aggravate Crohn's disease by inducing gut dysbiosis.
    Gut. 2025 Jun 8:gutjnl-2024-334604. doi: 10.1136/gutjnl-2024-334604.
    PubMed     Abstract available
    
    
    
35. BARNICH N, Arthur JC, Buisson A, Campbell BJ, et al
    Adherent-invasive Escherichia coli in Crohn's disease: the 25th anniversary.
    Gut. 2025 Jun 5:gutjnl-2025-335331. doi: 10.1136/gutjnl-2025-335331.
    PubMed     Abstract available
    
    
    May 2025
36. ALKHATEB O, Ftouni R, Abbas O, Mourad FH, et al
    Skin lesions and chest pain in a patient with Crohn's disease.
    Gut. 2025 May 24:gutjnl-2025-335547. doi: 10.1136/gutjnl-2025-335547.
    PubMed    
    
    
    
37. BLACKWELL J, Plevris N, Bancil A, Kobayashi T, et al
    Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025 May 13:gutjnl-2025-334946. doi: 10.1136/gutjnl-2025-334946.
    PubMed    
    
    
    
38. PAL P, Mateen MA, Sekaran A, Pooja K, et al
    Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?
    Gut. 2025 May 13:gutjnl-2025-335681. doi: 10.1136/gutjnl-2025-335681.
    PubMed    
    
    
    April 2025
39. EAST JE, Gordon M, Nigam GB, Sinopoulou V, et al
    British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease.
    Gut. 2025 Apr 30:gutjnl-2025-335023. doi: 10.1136/gutjnl-2025-335023.
    PubMed     Abstract available
    
    
    
40. TSCHURTSCHENTHALER M
    Dietary modulation of the gut phageome: a cross-kingdom dialogue in Crohn's disease.
    Gut. 2025 Apr 29:gutjnl-2025-335261. doi: 10.1136/gutjnl-2025-335261.
    PubMed    
    
    
    
41. WAN Z, Hao X, Huang F, Dai H, et al
    Unravelling the causality between inflammatory bowel disease and polycystic ovary syndrome mediated by gut microbiota and blood metabolism: insights from two prospective cohort studies.
    Gut. 2025 Apr 19:gutjnl-2024-334693. doi: 10.1136/gutjnl-2024-334693.
    PubMed    
    
    
    March 2025
42. SU R, Wen W, Jin Y, Cao Z, et al
    Dietary whey protein protects against Crohn's disease by orchestrating cross-kingdom interaction between the gut phageome and bacteriome.
    Gut. 2025 Mar 23:gutjnl-2024-334516. doi: 10.1136/gutjnl-2024-334516.
    PubMed     Abstract available
    
    
    
43. BAMIAS G, Menghini P, Pizarro TT, Cominelli F, et al
    Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.
    Gut. 2025;74:652-668.
    PubMed     Abstract available
    
    
    February 2025
44. GUISADO D, Talware S, Wang X, Davis A, et al
    Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
    Gut. 2025 Feb 17:gutjnl-2024-333558. doi: 10.1136/gutjnl-2024-333558.
    PubMed     Abstract available
    
    
    
45. GUDINO V, Bartolome-Casado R, Salas A
    Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications.
    Gut. 2025 Feb 4:gutjnl-2024-334165. doi: 10.1136/gutjnl-2024-334165.
    PubMed     Abstract available
    
    
    January 2025
46. AL BAKIR I, Curtius K, Cresswell GD, Grant HE, et al
    Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis.
    Gut. 2025 Jan 29:gutjnl-2024-333353. doi: 10.1136/gutjnl-2024-333353.
    PubMed     Abstract available
    
    
    
47. BONFILS L, Poulsen G, Agrawal M, Julsgaard M, et al
    Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population-based cohort study.
    Gut. 2025;74:206-213.
    PubMed     Abstract available
    
    
    
48. TE GROEN M, Wijnands AM, den Broeder N, de Jong DJ, et al
    Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS).
    Gut. 2025 Jan 16:gutjnl-2024-333446. doi: 10.1136/gutjnl-2024-333446.
    PubMed     Abstract available
    
    
    December 2024
49. ZHANG J
    Dysbiosis exists in unaffected relatives of inflammatory bowel disease (IBD): emphasising the critical phases in the developmental trajectory of gut microbiota.
    Gut. 2024 Dec 23:gutjnl-2024-333425. doi: 10.1136/gutjnl-2024-333425.
    PubMed    
    
    
    
50. GISBERT JP, Donday MG, Riestra S, Lucendo AJ, et al
    Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2024 Dec 20:gutjnl-2024-333385. doi: 10.1136/gutjnl-2024-333385.
    PubMed     Abstract available
    
    
    
51. ADLER J, Gadepalli S, Rahman M, Kim S, et al
    Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study.
    Gut. 2024 Dec 12:gutjnl-2024-333280. doi: 10.1136/gutjnl-2024-333280.
    PubMed     Abstract available
    
    
    
52. NEURATH MF, Sands BE, Rieder F
    Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
    Gut. 2024;74:9-14.
    PubMed     Abstract available
    
    
    November 2024
53. AMIOT A, Seksik P, Meyer A, Stefanescu C, et al
    Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
    Gut. 2024 Nov 25:gutjnl-2024-333281. doi: 10.1136/gutjnl-2024-333281.
    PubMed     Abstract available
    
    
    
54. WELLENS J, Sabino J, Vanuytsel T, Tack J, et al
    Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.
    Gut. 2024 Nov 12:gutjnl-2024-333565. doi: 10.1136/gutjnl-2024-333565.
    PubMed     Abstract available
    
    
    October 2024
55. LV X, Zeng Y, Ma W, Zheng Y, et al
    Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohn's disease.
    Gut. 2024 Oct 14:gutjnl-2024-333590. doi: 10.1136/gutjnl-2024-333590.
    PubMed    
    
    
    
56. VICH VILA A, Zhang J, Liu M, Faber KN, et al
    Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
    Gut. 2024;73:1909-1920.
    PubMed     Abstract available
    
    
    September 2024
57. ERKERT L, Gamez-Belmonte R, Kabisch M, Schodel L, et al
    Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.
    Gut. 2024;73:1618-1631.
    PubMed     Abstract available
    
    
    
58. CARPAY N, de Boer NKH, Neefjes-Borst A, Bots S, et al
    Severe multiple therapy refractory colitis in a 46-year-old man.
    Gut. 2024;73:1617-1736.
    PubMed    
    
    
    August 2024
59. ESTEVINHO MM, Midya V, Cohen-Mekelburg S, Allin KH, et al
    Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms.
    Gut. 2024 Aug 30:gutjnl-2024-332523. doi: 10.1136/gutjnl-2024-332523.
    PubMed     Abstract available
    
    
    
60. PIERRE N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, et al
    External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
    Gut. 2024 Aug 12:gutjnl-2024-332648. doi: 10.1136/gutjnl-2024-332648.
    PubMed     Abstract available
    
    
    
61. JACOBS JP, Spencer EA, Helmus DS, Yang JC, et al
    Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
    Gut. 2024 Aug 9:gutjnl-2024-332475. doi: 10.1136/gutjnl-2024-332475.
    PubMed     Abstract available
    
    
    
62. ATREYA R
    Glowing insights: tracking vedolizumab in the mucosa of patients with IBD via molecular endoscopy.
    Gut. 2024;73:1406-1408.
    PubMed    
    
    
    
63. VERSTOCKT B, Vancamelbeke M, Vermeire S
    Increased inflammatory state in IBD multiplex first-degree relatives not developing intestinal disease.
    Gut. 2024;73:1586-1588.
    PubMed    
    
    
    
64. MAJUMDER S, Santacroce G, Maeda Y, Zammarchi I, et al
    Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis.
    Gut. 2024 Aug 6:gutjnl-2024-332894. doi: 10.1136/gutjnl-2024-332894.
    PubMed    
    
    
    July 2024
65. DAI C, Huang YH
    Rare cause of liver lesion in a patient with ulcerative colitis.
    Gut. 2024 Jul 20:gutjnl-2024-333095. doi: 10.1136/gutjnl-2024-333095.
    PubMed    
    
    
    
66. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    PubMed    
    
    
    
67. ADOLPH TE, Meyer M, Jukic A, Tilg H, et al
    Heavy arch: from inflammatory bowel diseases to metabolic disorders.
    Gut. 2024;73:1376-1387.
    PubMed     Abstract available
    
    
    June 2024
68. DENNISON TW, Edgar RD, Payne F, Nayak KM, et al
    Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2024 Jun 10:gutjnl-2024-332043. doi: 10.1136/gutjnl-2024-332043.
    PubMed     Abstract available
    
    
    
69. IACUCCI M, Santacroce G, Majumder S, Morael J, et al
    Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia.
    Gut. 2024 Jun 8:gutjnl-2023-331579. doi: 10.1136/gutjnl-2023-331579.
    PubMed     Abstract available
    
    
    
70. LIN S, Wang J, Mukherjee PK, Mao R, et al
    Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis.
    Gut. 2024;73:1110-1123.
    PubMed     Abstract available
    
    
    
71. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    PubMed     Abstract available
    
    
    
72. HONAP S, Jairath V, Sands BE, Dulai PS, et al
    Acute severe ulcerative colitis trials: the past, the present and the future.
    Gut. 2024 Jun 4:gutjnl-2024-332489. doi: 10.1136/gutjnl-2024-332489.
    PubMed     Abstract available
    
    
    May 2024
73. MONAGHAN TM, Ugun-Klusek A, Finelli M, Gurnani P, et al
    Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention.
    Gut. 2024;73:1034-1036.
    PubMed    
    
    
    April 2024
74. GABRIELS RY, van der Waaij AM, Linssen MD, Dobosz M, et al
    Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
    Gut. 2024 Apr 5:gutjnl-2023-331696. doi: 10.1136/gutjnl-2023-331696.
    PubMed     Abstract available
    
    
    
75. RIEDER F, Mukherjee PK, Massey WJ, Wang Y, et al
    Fibrosis in IBD: from pathogenesis to therapeutic targets.
    Gut. 2024;73:854-866.
    PubMed     Abstract available
    
    
    
76. KARMI N, Sun S, Festen EAM, Vich Vila A, et al
    Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease.
    Gut. 2024 Apr 3:gutjnl-2024-332205. doi: 10.1136/gutjnl-2024-332205.
    PubMed    
    
    
    March 2024
77. ANANTHAKRISHNAN AN
    Inflammatory bowel diseases: are we ready to recommend a preventive diet for infants?
    Gut. 2024;73:559-560.
    PubMed    
    
    
    
78. SCHULZ-KUHNT A, Ruhle K, Javidmehr A, Dobronti M, et al
    ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
    Gut. 2024;73:601-612.
    PubMed     Abstract available
    
    
    February 2024
79. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    PubMed    
    
    
    
80. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    PubMed     Abstract available
    
    
    
81. ADOLPH TE
    It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease.
    Gut. 2024 Feb 20:gutjnl-2024-332016. doi: 10.1136/gutjnl-2024-332016.
    PubMed    
    
    
    
82. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.
    PubMed    
    
    
    January 2024
83. GUO A, Ludvigsson J, Brantsaeter AL, Klingberg S, et al
    Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts.
    Gut. 2024 Jan 30:gutjnl-2023-330971. doi: 10.1136/gutjnl-2023-330971.
    PubMed     Abstract available
    
    
    
84. SUN J, Yao J, Olen O, Halfvarson J, et al
    Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.
    Gut. 2024 Jan 6:gutjnl-2023-331632. doi: 10.1136/gutjnl-2023-331632.
    PubMed    
    
    
    
85. CHIRIAC MT, Hracsko Z, Gunther C, Gonzalez-Acera M, et al
    IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
    Gut. 2024;73:282-297.
    PubMed     Abstract available
    
    
    December 2023
86. ERIKSEN C, Danneskiold-Samsoe NB, Moll JM, Myers PN, et al
    Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease.
    Gut. 2023 Dec 16:gutjnl-2023-330677. doi: 10.1136/gutjnl-2023-330677.
    PubMed     Abstract available
    
    
    
87. MINERVINA AA, Pogorelyy MV, Paysen S, Luening U, et al
    Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
    Gut. 2023;73:205-206.
    PubMed    
    
    
    November 2023
88. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    PubMed     Abstract available
    
    
    
89. ULLRICH KA, Derdau J, Baltes C, Battistella A, et al
    IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.
    Gut. 2023;72:2081-2094.
    PubMed     Abstract available
    
    
    
90. NEURATH MF, Vieth M
    Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing.
    Gut. 2023;72:2164-2183.
    PubMed     Abstract available
    
    
    October 2023
91. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    PubMed    
    
    
    September 2023
92. MA Y, Zhang X, Xuan B, Li D, et al
    Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis.
    Gut. 2023 Sep 21:gutjnl-2023-330009. doi: 10.1136/gutjnl-2023-330009.
    PubMed     Abstract available
    
    
    
93. JIANG L, Li JC, Shen L, Tang BS, et al
    Association between inflammatory bowel disease and Alzheimer's disease: multivariable and bidirectional Mendelian randomisation analyses.
    Gut. 2023;72:1797-1799.
    PubMed    
    
    
    
94. CHURCHHOUSE AM, Moffat VE, Selinger CP, Lamb CA, et al
    British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance.
    Gut. 2023;72:1631-1634.
    PubMed    
    
    
    August 2023
95. SCHWARZLER J, Zollner A, Dolejsi T, Mayr L, et al
    Inflammatory bowel disease in STAT1 gain-of-function immunodeficiency treated with precision medicine.
    Gut. 2023 Aug 24:gutjnl-2023-330588. doi: 10.1136/gutjnl-2023-330588.
    PubMed    
    
    
    
96. CHETWOOD JD, Paramsothy S, Haifer C, Leong RW, et al
    Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis.
    Gut. 2023 Aug 17:gutjnl-2023-330196. doi: 10.1136/gutjnl-2023-330196.
    PubMed    
    
    
    
97. WAUTERS L, Tito RY, Ceulemans M, Outtier A, et al
    Microbiome variance of the small bowel in Crohn's disease.
    Gut. 2023;72:1626-1628.
    PubMed    
    
    
    July 2023
98. BECKER C, Adolph TE
    Disentangling tryptophan metabolism in inflammatory bowel diseases.
    Gut. 2023;72:1235-1236.
    PubMed    
    
    
    
99. LEE JC
    Going deeper: molecular inflammatory scores in IBD.
    Gut. 2023;72:1233-1234.
    PubMed    
    
    
    
100. MICHAUDEL C, Danne C, Agus A, Magniez A, et al
     Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
     Gut. 2023;72:1296-1307.
     PubMed     Abstract available
     
     
     
101. ARGMANN C, Hou R, Ungaro RC, Irizar H, et al
     Biopsy and blood-based molecular biomarker of inflammation in IBD.
     Gut. 2023;72:1271-1287.
     PubMed     Abstract available
     
     
     June 2023
102. DE BOER NKH, Simsek M, Meijer B, Neurath MF, et al
     Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
     Gut. 2023 Jun 28:gutjnl-2023-329679. doi: 10.1136/gutjnl-2023-329679.
     PubMed     Abstract available
     
     
     
103. LOPETUSO LR, Deleu S, Godny L, Petito V, et al
     The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
     Gut. 2023 Jun 20:gutjnl-2023-329948. doi: 10.1136/gutjnl-2023-329948.
     PubMed     Abstract available
     
     
     
104. SCHWARZFISCHER M, Niechcial A, Handler K, Morsy Y, et al
     TiO(2) nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.
     Gut. 2023;72:1101-1114.
     PubMed     Abstract available
     
     
     
105. MILLET V, Gensollen T, Maltese M, Serrero M, et al
     Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
     Gut. 2023;72:1115-1128.
     PubMed     Abstract available
     
     
     
106. DANNE C, Michaudel C, Skerniskyte J, Planchais J, et al
     CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
     Gut. 2023;72:1081-1092.
     PubMed     Abstract available
     
     
     May 2023
107. PAL P, Ramchandani M, Banerjee R, Viswakarma P, et al
     Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
     Gut. 2023 May 17:gutjnl-2023-329885. doi: 10.1136/gutjnl-2023-329885.
     PubMed     Abstract available
     
     
     
108. LU H, Zhang C, Wu W, Chen H, et al
     MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
     Gut. 2023;72:882-895.
     PubMed     Abstract available
     
     
     
109. ZUO L, Kuo WT, Cao F, Chanez-Paredes SD, et al
     Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
     Gut. 2023;72:870-881.
     PubMed     Abstract available
     
     
     April 2023
110. GHATE A, Uhlig HH
     Defective microbial sensing and clearance in perianal Crohn's disease: a role for complement factor B.
     Gut. 2023 Apr 25:gutjnl-2023-329801. doi: 10.1136/gutjnl-2023-329801.
     PubMed    
     
     
     
111. AKHLAGHPOUR M, Haritunians T, More SK, Thomas LS, et al
     Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
     Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689.
     PubMed     Abstract available
     
     
     
112. ZHAO J, Chen J, Sun Y, Yuan S, et al
     Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
     Gut. 2023 Apr 4:gutjnl-2023-329875. doi: 10.1136/gutjnl-2023-329875.
     PubMed    
     
     
     
113. YE BD
     Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
     Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.
     PubMed    
     
     
     
114. HSU NY, Nayar S, Gettler K, Talware S, et al
     NOX1 is essential for TNFalpha-induced intestinal epithelial ROS secretion and inhibits M cell signatures.
     Gut. 2023;72:654-662.
     PubMed     Abstract available
     
     
     
115. AGRAWAL M, Poulsen G, Colombel JF, Allin KH, et al
     Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study.
     Gut. 2023;72:804-805.
     PubMed    
     
     
     March 2023
116. FAYE AS, Jess T
     Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
     Gut. 2023 Mar 27:gutjnl-2023-329851. doi: 10.1136/gutjnl-2023-329851.
     PubMed    
     
     
     
117. VICH VILA A, Hu S, Andreu-Sanchez S, Collij V, et al
     Faecal metabolome and its determinants in inflammatory bowel disease.
     Gut. 2023 Mar 23:gutjnl-2022-328048. doi: 10.1136/gutjnl-2022-328048.
     PubMed     Abstract available
     
     
     
118. LAUBE R, Selinger CP, Seow CH, Christensen B, et al
     Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
     Gut. 2023 Mar 21:gutjnl-2022-329304. doi: 10.1136/gutjnl-2022-329304.
     PubMed     Abstract available
     
     
     
119. ZHANG E, Nguyen THO, Allen LF, Kedzierski L, et al
     Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.
     Gut. 2023 Mar 6:gutjnl-2022-329136. doi: 10.1136/gutjnl-2022-329136.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum